172 related articles for article (PubMed ID: 33727257)
1. Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial.
Vidal J; Casadevall D; Bellosillo B; Pericay C; Garcia-Carbonero R; Losa F; Layos L; Alonso V; Capdevila J; Gallego J; Vera R; Salud A; Martin-Richard M; Nogué M; Cillán E; Maurel J; Faull I; Raymond V; Fernández-Martos C; Montagut C
Clin Cancer Res; 2021 May; 27(10):2890-2898. PubMed ID: 33727257
[TBL] [Abstract][Full Text] [Related]
2. Assessing circulating tumour DNA (ctDNA) as a prognostic biomarker in locally advanced rectal cancer: a systematic review and meta-analysis.
O'Sullivan NJ; Temperley HC; Kyle ET; Sweeney KJ; O'Neill M; Gilham C; O'Sullivan J; O'Kane G; Mehigan B; O'Toole S; Larkin J; Gallagher D; McCormick P; Kelly ME
Int J Colorectal Dis; 2024 May; 39(1):82. PubMed ID: 38809315
[TBL] [Abstract][Full Text] [Related]
3. Total Neoadjuvant Therapy (TNT) versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis.
Liu S; Jiang T; Xiao L; Yang S; Liu Q; Gao Y; Chen G; Xiao W
Oncologist; 2021 Sep; 26(9):e1555-e1566. PubMed ID: 33987952
[TBL] [Abstract][Full Text] [Related]
4. Implication of Pre- and Post-radiotherapy ctDNA Dynamics in Patients with Residual Triple-Negative Breast Cancer at Surgery after Neoadjuvant Chemotherapy: Findings from a Prospective Observational Study.
Lee TH; Kim H; Kim YJ; Park WY; Park W; Cho WK; Kim N
Cancer Res Treat; 2024 Apr; 56(2):531-537. PubMed ID: 37946409
[TBL] [Abstract][Full Text] [Related]
5. The role of total neoadjuvant therapy in locally advanced rectal cancer: a survey of specialists attending the All-Ireland Colorectal Cancer Conference 2022 including lead investigators of OPRA, PRODIGE-23 and RAPIDO.
O'Brien T; Hospers G; Conroy T; Lenz HJ; Smith JJ; Andrews E; O'Neill B; Leonard G
Ir J Med Sci; 2024 Jun; 193(3):1183-1190. PubMed ID: 38141097
[TBL] [Abstract][Full Text] [Related]
6. Future direction of total neoadjuvant therapy for locally advanced rectal cancer.
Kagawa Y; Smith JJ; Fokas E; Watanabe J; Cercek A; Greten FR; Bando H; Shi Q; Garcia-Aguilar J; Romesser PB; Horvat N; Sanoff H; Hall W; Kato T; Rödel C; Dasari A; Yoshino T
Nat Rev Gastroenterol Hepatol; 2024 Jun; 21(6):444-455. PubMed ID: 38485756
[TBL] [Abstract][Full Text] [Related]
7. Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer.
Duda DG; Willett CG; Ancukiewicz M; di Tomaso E; Shah M; Czito BG; Bentley R; Poleski M; Lauwers GY; Carroll M; Tyler D; Mantyh C; Shellito P; Clark JW; Jain RK
Oncologist; 2010; 15(6):577-83. PubMed ID: 20484123
[TBL] [Abstract][Full Text] [Related]
8. ctDNA as a predictor of outcome after curative resection for locally advanced rectal cancer: systematic review and meta-analysis.
Nassar A; Aly NE; Jin Z; Aly EH
Colorectal Dis; 2024 May; ():. PubMed ID: 38802990
[TBL] [Abstract][Full Text] [Related]
9. Advancing Personalized Medicine in the Treatment of Locally Advanced Rectal Cancer.
Sullo FG; Passardi A; Gallio C; Molinari C; Marisi G; Pozzi E; Solaini L; Bittoni A
J Clin Med; 2024 Apr; 13(9):. PubMed ID: 38731090
[TBL] [Abstract][Full Text] [Related]
10. The use of circulating cell-free tumor DNA in routine diagnostics of metastatic melanoma patients.
Knuever J; Weiss J; Persa OD; Kreuzer K; Mauch C; Hallek M; Schlaak M
Sci Rep; 2020 Mar; 10(1):4940. PubMed ID: 32188904
[TBL] [Abstract][Full Text] [Related]
11. Circulating Tumor DNA (ctDNA) Clearance May Predict Treatment Response in Neoadjuvant Colorectal Cancer Management.
Niemann B; Moise J; Sestito M; Malla M; Train K; Murken D; Mayers K; Groves E; Garland-Kledzik M
J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38541909
[No Abstract] [Full Text] [Related]
12. The multidisciplinary management of locally advanced rectal cancer.
De Felice F; Miccini M; Botticelli A; Roberto M; Petrucciani N
Expert Rev Anticancer Ther; 2024 Apr; ():1-7. PubMed ID: 38676281
[TBL] [Abstract][Full Text] [Related]
13. Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer.
Parikh AR; Van Seventer EE; Siravegna G; Hartwig AV; Jaimovich A; He Y; Kanter K; Fish MG; Fosbenner KD; Miao B; Phillips S; Carmichael JH; Sharma N; Jarnagin J; Baiev I; Shah YS; Fetter IJ; Shahzade HA; Allen JN; Blaszkowsky LS; Clark JW; Dubois JS; Franses JW; Giantonio BJ; Goyal L; Klempner SJ; Nipp RD; Roeland EJ; Ryan DP; Weekes CD; Wo JY; Hong TS; Bordeianou L; Ferrone CR; Qadan M; Kunitake H; Berger D; Ricciardi R; Cusack JC; Raymond VM; Talasaz A; Boland GM; Corcoran RB
Clin Cancer Res; 2021 Oct; 27(20):5586-5594. PubMed ID: 33926918
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
15. The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer.
Arai H; Elliott A; Xiu J; Wang J; Battaglin F; Kawanishi N; Soni S; Zhang W; Millstein J; Sohal D; Goldberg RM; Hall MJ; Scott AJ; Khushman M; Hwang JJ; Lou E; Weinberg BA; Marshall JL; Lockhart AC; Stafford P; Zhang J; Moretto R; Cremolini C; Korn WM; Lenz HJ
Clin Cancer Res; 2021 Jun; 27(11):3234-3242. PubMed ID: 33766816
[TBL] [Abstract][Full Text] [Related]
16. Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development.
Pal A; Shinde R; Miralles MS; Workman P; de Bono J
Nat Rev Clin Oncol; 2021 Jul; 18(7):454-467. PubMed ID: 33762744
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
[TBL] [Abstract][Full Text] [Related]
18. BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database.
Cohen R; Liu H; Fiskum J; Adams R; Chibaudel B; Maughan TS; Van Cutsem E; Venook A; Douillard JY; Heinemann V; Ja Punt C; Falcone A; Bokemeyer C; Kaplan R; Lenz HJ; Koopman M; Yoshino T; Zalcberg J; Grothey A; de Gramont A; Shi Q; André T
J Natl Cancer Inst; 2021 Oct; 113(10):1386-1395. PubMed ID: 33734401
[TBL] [Abstract][Full Text] [Related]
19. Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations.
Adib E; Klonowska K; Giannikou K; Do KT; Pruitt-Thompson S; Bhushan K; Milstein MI; Hedglin J; Kargus KE; Sholl LM; Tsuji J; Hyman DM; Sisk A; Shapiro GI; Vargas HA; Harding JJ; Voss MH; Iyer G; Kwiatkowski DJ
Clin Cancer Res; 2021 Jul; 27(14):3845-3853. PubMed ID: 33727259
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.
Conroy T; Bosset JF; Etienne PL; Rio E; François É; Mesgouez-Nebout N; Vendrely V; Artignan X; Bouché O; Gargot D; Boige V; Bonichon-Lamichhane N; Louvet C; Morand C; de la Fouchardière C; Lamfichekh N; Juzyna B; Jouffroy-Zeller C; Rullier E; Marchal F; Gourgou S; Castan F; Borg C;
Lancet Oncol; 2021 May; 22(5):702-715. PubMed ID: 33862000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
